CIK 1704132
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 56.94% | 1 |
| Pharmaceuticals & Biotechnology | 43.06% | 7 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | PHVS | PHARVARIS N V | Unclassified | 56.94% |
| 2 | CYTK | CYTOKINETICS INC | Health Care | 13.99% |
| 3 | EIKN | Eikon Therapeutics, Inc. | Health Care | 8.67% |
| 4 | LYEL | Lyell Immunopharma, Inc. | Health Care | 6.77% |
| 5 | RLAY | Relay Therapeutics, Inc. | Health Care | 4.20% |
| 6 | XENE | Xenon Pharmaceuticals Inc. | Health Care | 3.92% |
| 7 | ALEC | Alector, Inc. | Health Care | 3.53% |
| 8 | MAZE | Maze Therapeutics, Inc. | Health Care | 1.98% |
7/8 names classified · sector 43.1% of weight · industry 43.1% · mkt cap 43.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 43.1% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/8 names) · unclassified 100.0%: PHVS, CYTK, EIKN, LYEL, RLAY, XENE, ALEC, MAZE. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | PHVSPHARVARIS N V | 4,778,581 | $135M | 56.9% | HOLD |
| 2 | CYTKCYTOKINETICS INC | 503,295 | $33M | 14.0% | ADD 10% |
| 3 | EIKNEIKON THERAPEUTICS INC | 1,943,682 | $21M | 8.7% | NEW |
| 4 | LYELLYELL IMMUNOPHARMA INC | 800,399 | $16M | 6.8% | HOLD |
| 5 | RLAYRELAY THERAPEUTICS INC | 1,000,000 | $10M | 4.2% | HOLD |
| 6 | XENEXENON PHARMACEUTICALS INC | 160,000 | $9M | 3.9% | HOLD |
| 7 | ALECALECTOR INC | 3,887,200 | $8M | 3.5% | HOLD |
| 8 | MAZEMAZE THERAPEUTICS INC | 156,901 | $5M | 2.0% | TRIM −70% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| PHVSPHARVARIS N V | 4.4M | 4.4M | 4.4M | 4.8M | 4.8M | 4.8M | $135M |
| CYTKCYTOKINETICS INC | — | — | — | 458K | 458K | 503K | $33M |
| EIKNEIKON THERAPEUTICS INC | — | — | — | — | — | 1.9M | $21M |
| LYELLYELL IMMUNOPHARMA INC | — | — | 800K | 800K | 800K | 800K | $16M |
| RLAYRELAY THERAPEUTICS INC | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | $10M |
| XENEXENON PHARMACEUTICALS INC | — | — | 160K | 160K | 160K | 160K | $9M |
| ALECALECTOR INC | — | — | — | — | 3.9M | 3.9M | $8M |
| MAZEMAZE THERAPEUTICS INC | — | 2.1M | 2.1M | 523K | 523K | 157K | $5M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
